Randomised Phase II Study to Assess the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schedules (rAd26-rAd5, rAd26-rAd26, rAd26-ChAdOx1 and rAd26-mRNA-1273).
This Phase II clinical trial, sponsored by the Ministerio de Salud de Ciudad Autónoma de Buenos Aires, aims to evaluate the immunogenicity and safety of heterologous SARS-CoV-2 vaccine regimens in a population that has previously received a dose of the Gam-COVID-Vac vaccine. Given the logistical challenges in vaccine distribution and the emergence of new variants, the trial addresses a critical public health need in Argentina, where a significant number of individuals are partially vaccinated. If successful, the results could support the adoption of heterologous vaccination strategies, potentially expanding the market for vaccine manufacturers involved in the study and enhancing public health responses to COVID-19. The competitive landscape may shift as data emerges regarding the efficacy of these combinations, influencing future vaccine development and approval processes.
Indication: COVID-19 Vaccines
Modality: monoclonal antibody
Target: SARS-CoV-2 Spike Protein (protein S)
Sponsor: Ministerio de Salud de Ciudad Autónoma de Buenos Aires
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 10, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: SARS-CoV-2 Spike Protein (protein S)
View original source fields
Condition raw: COVID-19 Vaccines
Condition normalized: COVID-19 Vaccines
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: SARS-CoV-2 Spike Protein (protein S)
Target normalized: SARS-CoV-2 Spike Protein (protein S)